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Abstract 
The MET oncogene, a crucial regulator of the genetic program known as “invasive growth” or “epithelial–
mesenchymal transition,” has recently emerged as a functional marker of glioblastoma stem cells. Here, we 
review findings that associate MET expression and activity with a specific, genetically defined glioblastoma 
stem cell subtype, and data showing how MET sustains the stem cell phenotype in glioblastoma and other 
tumors. Finally, we discuss issues related to identification of tumorigenic clones driven by MET in the context 
of genetically heterogeneous tumors and strategies aimed at eradicating cancer stem cells.  
 
Glioblastoma: A Model for the Quest of Tumor Genetic Determinants and 
Tumorigenic Cell Hierarchies 
Glioblastoma, the most common type of brain tumor, is relatively rare but virtually incurable, with a median 
survival of 12 to 15 months attained through combination of surgery, radiotherapy, and chemotherapy with 
the DNA alkylating/methylating agent temozolomide (1). This multimodal protocol often fails because the 
locally infiltrative nature of the tumor may limit surgical resection, brain side effects restrain the dose of 
radiotherapy, expression of the DNA repair enzyme O-6 methyl-guanine methyltransferase (MGMT) confers 
resistance against temozolomide, and the blood–brain barrier blocks alternative chemotherapeutic agents (2, 
3). With the exception of antiangiogenic agents, inhibitors of tyrosine kinase receptors, or signal transducers 
controlling cell proliferation, did not provide any benefit in clinical trials (4). Recurrence has been associated 
with innate DNA repair activity and radioresistance of the “cancer stem cell” subpopulation (5). Glioblastoma 
is indeed one of the first solid tumors in which a cell hierarchy including tumorigenic (stem) and 
nontumorigenic (nonstem) cancer cells has been identified by the in vivo transplantation assay (6, 7). At the 
same time, a comprehensive picture of the glioblastoma genomic landscape has been provided (reviewed in 
ref. 8). Genes recurrently altered—and thus likely to play a significant pathogenic role—frequently impinge 
on three main signaling circuits: (i) the receptor tyrosine kinase/Ras/phosphoinositide 3-kinase (PI3K) 
pathway, controlling cell proliferation and survival [This includes the EGF receptor (EGFR, amplified and/or 
mutated in 45% cases, the most frequent mutation being deletion of the extracellular domain, also known 
as EGFRvIII deletion). Other affected genes are the PI3K inhibitor PTEN(inactivated in 36% of cases) and 
the Ras inhibitor NF1 (inactivated in 23% of cases)]; (ii) the p53 pathway, controlling apoptosis and 
senescence, where TP53 is mutated in 35% of cases; and (iii) the RB pathway, controlling cell-cycle 
progression, where the cell-cycle inhibitors CDKN2A (p16/INK4A) and CDKN2B are alternatively inactivated 
in about 50% of cases. Overall, about 75% of patients harbor at least one gene alteration in each of the 
above three pathways (2, 8). Another recently emerged pathway is NF-º B, with deletion ofNFº BIA affecting 
about 25% of patients (9). Quite unexpectedly, a relatively high frequency of mutations was also found in the 
Krebs cycle enzymes isocitrate dehydrogenase 1 and 2 (IDH1/2). These mutations are preferentially 
associated with “secondary glioblastoma,” that is, glioblastoma progressing from lower grade gliomas, where 
they affect 80% of cases, with a significant pathogenetic role (10).  As the inventory of glioblastoma-driving 
genes enlarges, the connectivity among the crucial players is becoming clearer. However, the dynamics by 
which mutations accumulate is still obscure, particularly in “primary glioblastomas,” that is, tumors diagnosed 
at their onset as “high-grade” (10). Intratumor genetic heterogeneity—the presence of different genetic 
lesions in distinct cell subsets—is a common cancer feature, and glioblastoma makes no exception 
(reviewed in ref. 11). Intriguingly, this heterogeneity might reflect coexistence of subclones sustained by 
genetically distinct cancer stem cells. Indeed, it has been proposed that cancer stem cells can be not only a 
source of tumor phenotypic heterogeneity (resulting from progeny pseudodifferentiation) but also the units of 
tumor genetic evolution, obeying the Darwinian laws of mutation and selection (12, 13). Studies in leukemias 
have shown that multiple, genetically distinct subclones of cancer stem cells may coexist (14). These 
sublcones likely result from “divergent evolution” of a common ancestor cancer stem cell, which generates 
parallel lineages undergoing independent mutation accrual and clonal selection (12–14). Interestingly, 
genetically distinct, but related, cancer stem cells have been isolated from different areas of the same 
glioblastoma (15), suggesting that, also in this tumor, divergent evolution and coexistence of different cancer 
stem cell subclones may occur, although a dominant subclone may prevail. 
Concomitant analysis of genetic alterations and gene expression profiles of glioblastomas provided a 
molecular classification into four main subtypes (proneural, neural, classical, and mesenchymal; ref. 16). In 
this classification, some genetic alterations are preferentially associated with a specific gene expression 
profile. For instance, high-level amplification and/or mutation of EGFR gene, together with high expression of 
EGFR protein, are significantly more frequent in tumors displaying the classical or the neural profile, as 
compared with the proneural or mesenchymal ones. Platelet-derived growth factor (PDGF) receptor 
or IDH1/2 alterations define the proneural profile, whereas NF1deletion is mostly associated with the 
mesenchymal. Conversely, another frequent gene alteration such as PTEN inactivation may associate with 
any gene expression profile (16). Interestingly, glioblastomas that relapse after undergoing the selective 
pressure of chemoradiotherapy usually display a mesenchymal profile (16). This suggests that, in the 
primary tumor, a mesenchymal subclone inherently resistant to therapies may coexist with a dominant 
classical or proneural subclone and drive relapse when such dominant clone is exterminated. 
 
The MET Oncogene: A Marker of a Glioblastoma Stem Cell Subset 
 
Beside EGFR, other receptor tyrosine kinase genes are altered in a significant fraction of 
glioblastomas: HER-2 (ERBB2, 8%), PDGF receptor A (13%), and MET (HGF receptor, 4%). Although its 
genetic alteration is relatively rare, MET is suspected to play a wide role in glioblastoma pathogenesis, as it 
is often overexpressed and coexpressed with its ligand, hepatocyte growth factor (HGF; refs. 17–19). The 
frequency of MET expression in primary glioblastoma, measured by immunohistochemical methods, varies 
from 100% (likely overestimated because of the different levels of intensity among samples; ref. 17) to 
approximately 30% of cases (20). Interestingly, MET is expressed also by endothelial cells and can 
significantly contribute to glioblastoma neoangiogenesis (19). Through gene expression 
profiling, MET turned out to be a “signature gene,” specifically associated with the glioblastoma 
mesenchymal subtype (30% of primary glioblastomas; refs. 16, 21). 
The study of MET expression and function, as well as other tyrosine kinase receptors, in glioblastoma stem 
cells has been facilitated by in vitro isolation and long-term propagation of glioblastoma neurospheres 
(hereafter referred to simply as “neurospheres”), that is, extensively self-renewing cultures enriched in 
glioblastoma stem and progenitor cells (7). In neurospheres, both EGFR and MET were shown to sustain the 
stem and tumorigenic phenotype (22, 23). More recently, MET expression was associated with glioblastoma 
stem cells identified by prospective isolation from fresh tumors (24) or with neurospheres endowed with 
specific genetic/molecular features (25). The study by Joo and colleagues shows that MET expression is 
heterogeneous within the same tumor, with dominant expression in two apparently unrelated regions: the 
proximities of blood vessels and the hypoxic edges (24). The first region may correspond to the “perivascular 
niche,” a microenvironment required to maintain glioblastoma stem cell properties (26). Hypoxic areas, which 
are far from blood vessels and adjacent to necrotic areas, have been already functionally associated with 
MET in many tumors, since a transcriptional factor activated by hypoxia [hypoxia-inducible factor 1 (HIF-1)] 
directly promotes transcription of the METgene (27). Prospective isolation of glioblastoma cell 
subpopulations with anti-MET antibodies showed that only cells expressing high levels of MET retained 
clonogenic, tumorigenic, and radioresistant properties—that is, a cancer stem cell phenotype (ref. 24;Fig. 1). 
 
Figure 1. 
MET as a functional marker of glioblastoma stem cells. A, from glioblastomas, two subtypes of neurospheres (cultures 
enriched in stem and progenitor cells) can be isolated that alternatively lack or display MET expression (MET-negative or 
MET-positive, respectively). Lack of MET expression significantly correlates with EGFR gene amplification/mutation 
(EGFRamp/vIII), “wild-type” PTENgene (PTENwt), and a classical gene expression profile (subtype). Conversely, MET 
expression preferentially associates with a “wild-type” EGFRgene (EGFRwt), PTEN gene inactivation (PTENloss), and a 
mesenchymal or proneural gene expression profile. In MET-positive neurospheres, a cell hierarchy can be found. The 
METhigh subpopulation displays clonogenic and tumorigenic properties and radioresistance. METhigh cells self-renew and 
generate cells that downregulate MET expression (METneg) and lose stem/tumorigenic properties. METhigh cells can also 
be directly isolated from glioblastoma tissues. The cell hierarchy in MET-negative neurospheres is presently unknown. B, 
MET expression may be constitutive (“inherence,” see text) but also increased by environmental factors (“expedience,” 
see text). In METhigh cells, HGF drives a genetic program that sustains clonogenicity, invasiveness, tumorigenesis, and 
radioresistance. 
The study by De Bacco and colleagues associated MET expression with a subset of neurospheres endowed with specific 
genetic features (25). MET is usually absent from neurospheres displaying EGFR amplification/mutation (MET-negative 
neurospheres, Fig. 1). Conversely, MET is usually expressed in neurospheres harboring a normal EGFRgene 
and PTEN inactivation (MET-positive neurospheres, Fig. 1). A corollary observation of this study is that while in the tumor 
tissue EGFR amplification/mutation (EGFRamp/vIII) and PTEN inactivation (PTENloss) often coexist, in neurospheres the 
two genetic lesions dissociate (Fig. 1). Interestingly, in the same study, a subgroup of original tumors harboring 
both EGFRamp/vIII and PTENloss yielded neurospheres with normal EGFR gene (EGFRwt) and PTENloss (25). These 
observations, although based on a small number of cases, suggest that (i) glioblastomas harboring 
both EGFRamp/vIII and PTENloss contain at least two subclones of cancer stem cells, respectively, PTENloss-
EGFRwt andPTENloss-EGFRamp/vIII; (ii) from the same tumors, in vitro culture positively selectsPTENloss-
EGFRwt subclones; and (iii) in glioblastoma progression, PTEN inactivation should occur 
before EGFR amplification/mutation, a conclusion sustained also by predictive mathematical models (28). 
MET expression was also associated with defined neurosphere gene expression profiles (25). Classification on the basis 
of the signatures identified by Verhaak and colleagues in glioblastoma tissues (16) indicated that MET-positive 
neurospheres mostly belonged to the mesenchymal subtype, an association already observed in glioblastoma tissues 
(16,21). However, quite unexpectedly, some Met-positive neurospheres were classified as proneural. Conversely, MET-
negative neurospheres mostly belonged to the classical subtype, thus conserving the same relationship 
between EGFR gene amplification/mutation and classical gene expression profile observed in glioblastoma tissues (Fig. 
1). 
 
MET Sustains the Stem, Tumorigenic, and Invasive Phenotype in Glioblastoma 
It is well known that the HGF/MET ligand–receptor pair plays a functional role in glioblastoma as well as in 
other cancer cell lines by driving the “invasive growth” program. This is a complex biologic process starting 
with epithelial–mesenchymal transition (EMT) and leading to cell invasion, proliferation, and survival in 
atypical tissue environments, including distant metastatic sites (reviewed in ref. 29). Recent evidence 
indicating that common molecular mechanisms control both EMT and “stemness” (30) suggests that MET 
may be involved in the concomitant regulation of both properties. 
Three recently published articles support the conclusion that MET is a functional marker of glioblastoma 
stem cells. Li and colleagues showed that MET stimulation by HGF sustains clonogenic properties of 
neurospheres and expression of a panel of transcription factors, including Sox2, c-Myc, Klf4, Oct4, and 
Nanog, capable of reprogramming differentiated cells into pluripotent stem cells (ref. 23; Fig. 1). The studies 
by Joo and colleagues (24) and De Bacco and colleagues (25) corroborate the ability of MET to sustain the 
glioblastoma stem cell phenotype in vitro and report a tight association between MET expression and 
tumorigenic properties in vivo. However, MET is not a universal marker of glioblastoma stem cells. Indeed, 
MET-negative neurospheres fully endowed with self-propagation and tumorigenic properties can be derived, 
mostly from glioblastomas harboring EGFR gene amplification/mutation (Fig. 1). Unlike MET-positive 
neurospheres, MET-negative neurospheres are strongly dependent on EGFR activation for their in 
vitro propagation and, likely, for their in vivo tumorigenic potential (25). 
Interestingly, MET-positive neurospheres do not homogenously express MET and seem to be organized in a 
cell hierarchy featuring, at the apex, a cell subpopulation expressing high levels of MET (METhigh) and, at the 
base, a cell subpopulation that conversely expresses negligible levels of MET (METneg; Fig. 1). This 
conclusion is supported by data showing that upon isolation from neurospheres, (i) METhigh, but not 
METneg cells, retain distinctive stem cell properties such as long-term propagation (clonogenic ability) and 
multipotential differentiation; (ii) METhigh, but not METneg cells, can reconstitute a mixed METhigh-METneg cell 
population, as found in the original neurosphere; and (iii) METhighhave increased tumorigenic ability as 
compared with METneg and are the only that form tumors containing both METhigh and METneg cells (25). 
Moreover, it was shown that when neurospheres undergo a differentiative program (e.g., by culture in serum) 
MET expression is downregulated, again suggesting that MET is specifically associated with the stem status 
(25). 
Finally, in MET-positive neurospheres, HGF increases in vitro migration through extracellular matrices, a 
typical property of “mesenchymal” cells, predictive of invasive ability in vivo, thus suggesting that MET may 
concomitantly regulate stem and EMT/invasiveness (Fig. 1; ref. 25). 
 
MET Expression and Function in Cancer Stem Cells: A Paradigm of “Inherence” 
Together with leukemias, glioblastoma is a model for the genetic and phenotypic study of cancer stem cells 
in many tumor types. High incidence tumors, such as breast, lung, and colorectal carcinomas, underwent 
extensive genetic characterization, but investigation on how mutations affect the cancer stem cell phenotype 
has just begun. With the advent of targeted therapies, this knowledge is necessary to clarify: (i) whether a 
given target is expressed and functionally meaningful in the dominant stem cell subpopulation, which would 
determine whether the arising tumor will be sensitive or primarily resistant to target inhibition; and (ii) 
whether, in the same tumor, there are coexisting cell subclones with stem potential primarily resistant to, and 
therefore selectable by, therapy to become the driver of tumor recurrence. This is exemplified by a minor 
subset of MET-amplified cells resistant to EGFR inhibitors, which drives recurrence in non–small cell lung 
carcinoma after treatment with gefitinib (31). 
There is little knowledge about expression and function of MET in cancer stem cells outside the brain; 
however, direct and indirect evidence points to an ample involvement in defining tumorigenic subpopulations. 
In colorectal cancer, this oncogene is frequently overexpressed, mostly in association with poor prognosis 
(32). It has been shown that colorectal cancer stem cells express MET, activated by the HGF abundantly 
secreted by tumor-associated fibroblasts, which supports the stem phenotype by sustaining the Wnt self-
renewal pathway (33). An indication that MET plays a role in breast cancer stem cells comes from the study 
of cell hierarchies in the mouse mammary gland: Here, MET is specifically expressed in the “luminal 
progenitor” subpopulation (34), a likely origin of the basal-like cancer subtype (35), where the oncogene is 
frequently overexpressed (36). Indeed, in many tumors, the MET gene is rarely mutated (or amplified) but 
often overexpressed in the absence of genetic alterations (reviewed in refs. 32, 37). Recently, we proposed 
that this overexpression is an adaptive response to a threat, providing a mechanism of escape from danger, 
and an oncogenic boost (“oncogene expedience;” ref.32). Hypoxia, inflammatory cues, and ionizing radiation 
are among the adverse environmental conditions leading to activation of specific signaling pathway and 
transcriptional mechanisms (HIF, NF-º B) that upregulate MET. The oncogene, in turn, unleashes a powerful 
prosurvival signal and, eventually, escape from the “mined” territory through invasion and metastasis 
(27, 38). 
We now propose that, in addition to expedience, MET overexpression by tumors is a paradigm of 
“inherence.” This means innate MET expression by cancer stem cells that “inherit” MET as a physiologic trait 
from their normal counterparts, that is, the stem and progenitor cells that practice invasive growth as part of 
their normal phenotype (39). In this context, MET overexpression in tumors is due not only to transcriptional 
induction at single-cell level but also to expansion of the stem/progenitor subpopulation of cells inherently 
expressing MET (39). Indeed, MET expression and activity has been shown to support amplification and 
self-renewal of murine adult neural stem cells of the subventricular zone (40), the most likely, although not 
the only possible, glioblastoma cells of origin (10). Expansion of the cell compartment expressing MET is 
consistent with accumulation of stem/progenitors resulting from the differentiation block imposed by 
oncogenic transformation. This block may worsen during tumor progression and possibly lead to the 
equivalent of a leukemic “blastic crisis.” 
 
Implications of MET Expression in Cancer Stem Cells for Diagnosis and 
Personalized Therapy of Glioblastoma (and Other Tumors) 
The presence of different mutations in cancer stem cells, their accumulation over time in linear or in 
branching subclones, and the likely coexistence of genetically distinct subclones has important 
consequences: (i) the inter- and intratumor variegate genetics of cancer stem cells undermines the response 
to targeted therapies; (ii) the intratumor variability of cancer stem cells dictates the need to hit simultaneously 
different coexisting subclones; and (iii) the survival of any minor clone—unaffected by therapy—drives 
positive selection and recurrence. 
A trivial explanation for failures of clinical trials with targeted therapies in glioblastoma may be the presence 
of the blood–brain barrier that opposes an obstacle to drug delivery. However, in glioblastoma as well as in 
other tumors not shielded by a blood–tissue barrier, a deeper interpretation of these failures is the 
heterogeneous and dynamic genetics of cancer stem cells. In glioblastoma, the high frequency 
of EGFRamplification/mutation fostered EGFR inhibitors. Despite initial success in patients displaying 
specific molecular features, such as expression of EGFRvIII and PTENintegrity (41), subsequent trials failed 
(42). As result, therapy of glioblastoma with EGFR inhibitors was stopped. However, from these studies, it is 
difficult to draw a final negative conclusion, as a different outcome could arise from careful stratification of 
patients by considering the full spectrum of genetic alterations and recognizing the presence of coexisting 
subclones harboring genetic lesions other than EGFR. Similar considerations must be taken into account in 
planning “personalized” targeted therapy against MET. As mentioned above, the oncogene is amplified only 
in a small subset of glioblastomas (4%), but it is expressed in a high percentage of cases, often in 
association with its ligand HGF, which is predictive of sensitivity to MET inhibition in mouse models (43). 
Moreover, as discussed, MET may contribute to sustain the stem cell phenotype of a fraction of 
glioblastomas by “oncogenic inherence” (see above). However, as suggested also by a phase II clinical trial 
with the anti-HGF antibody AMG-102 (44), it is unlikely that MET targeting alone could provide a substantial 
benefit in glioblastoma therapy. On the other hand, preclinical studies have shown that MET inhibitors 
synergize with EGFR against xenografts of glioblastoma cell lines harboring both EGRvIII mutation 
and PTEN deletion (45). Therefore, better identification of patients that will benefit from MET inhibitors could 
be achieved by (i) a careful analysis of the genetic alterations coexisting with MET amplification and/or 
expression and (ii) an accurate identification of the genetically distinct subclones coexisting in the tumor. 
This may not be an easy task but technology will help in the near future (e.g., “next generation” sequencing, 
cell sorting, identification of “surrogate markers,” and co-clinical trials in “xenopatients”; refs. 46–48). Looking 
forward to achieving these technological breakthroughs, two state-of-the-art approaches are currently 
available: combination of MET targeted therapy with either radiotherapy or anti-angiogenic agents. 
 
MET Inhibitors, Radiotherapy, and Antiangiogenesis 
We recently showed that doses of ionizing radiation commonly used for tumor radiotherapy 
induce MET transcriptional upregulation in glioblastomas and other tumor types (38). The signaling pathway 
leading to MET overexpression starts with ATM kinase, involved in recognition of DNA damage, and ends 
with the transcription factor NF-º B that activates the MET promoter. Overexpression results in ligand-
independent MET activation, sensitization to subliminal concentrations of HGF, protection against radiation-
induced apoptosis, and, notably, induction of invasive growth. Vice versa, MET inhibition by small-molecule 
kinase inhibitors or monoclonal antibodies radiosensitizes tumor cells in vitroand in vivo (38). Interestingly, 
Joo and colleagues in their recent article showed that MET is induced by ionizing radiation in glioblastoma 
stem cells, and its inhibition counteracts their inherent radioresistance (24). Altogether, these findings 
strongly suggest that association of radiotherapy with MET inhibitors could increase the chance to eradicate 
the glioblastoma stem cell population (Fig. 1). The anti-VEGF antibody bevacizumab, targeting tumor 
neoangiogensis, and currently approved as single agent for recurrent glioblastoma, has provided only a 
modest therapeutic benefit (49). Indeed, bevacizumab induces a transient tumor regression, almost 
invariably ending in resistance and progression. In most cases, the tumor regains the ability to form blood 
vessels, while in the remaining cases (up to 30%), the tumor relapses with a seemingly infiltrative and 
angiogenic-independent pattern (50). Although lack of standardized imaging criteria to define relapse makes 
these findings controversial, an invasive response likely takes place after blood vessel inhibition (reviewed in 
ref. 51). Increasing experimental evidence points to MET as a major culprit. Indeed, reduced blood influx 
leads to decreased intracellular oxygen concentration and MET transcriptional upregulation by HIF-1 (see 
above; ref. 27). Further in this line, a recent article proposes that the invasive response to bevacizumab may 
also arise from the reversal by bevacizumab of VEGF-dependent MET receptor inhibition (52). Although the 
role of stem cells in the response to bevacizumab remains unknown at this time, these findings predict that 
association of MET and angiogenesis inhibitors would be beneficial to prevent the tumor “proinvasive 
response” to blood deprivation. 
Conclusions 
Analysis of neurospheres and cells prospectively isolated from fresh tumors allowed to identify MET as a 
functional marker of glioblastoma stem cells. MET expression is significantly associated with specific genetic 
features, such as normal EGFR gene andPTEN inactivation, and with defined gene expression profiles 
(mesenchymal-proneural). Upon stimulation by its ligand, MET contributes to glioblastoma stem cell self-
renewal, invasiveness, tumorigenesis, and radioresistance. Genetic heterogeneity of glioblastomas and 
neurospheres suggest that multiple stem cell subclones, with distinct genetic alterations and different 
expression of MET, coexist in the same tumor. These observations have important consequences for 
identification of patients that could benefit of targeted therapies against MET and/or other meaningful targets 
in glioblastoma and other tumors. MET involvement in resistance to ionizing radiation or antiangiogenic 
agents suggests that MET inhibition may be useful in combination with radiotherapy or antiangiogenic 
treatments such as bevacizumab. 
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